Sofosbuvir

A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.

Also Known As:

2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester; GS-7977; PSI 7977; PSI-7977; PSI7977; Sovaldi; 7977, PSI; GS 7977; GS7977

Networked: 1518 relevant articles (252 outcomes, 313 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	McHutchison, John G: 56 articles (01/2021 - 04/2013)
2.	Brainard, Diana M: 52 articles (01/2021 - 05/2014)
3.	Lawitz, Eric: 32 articles (01/2022 - 01/2013)
4.	Zeuzem, Stefan: 32 articles (01/2021 - 05/2014)
5.	Dvory-Sobol, Hadas: 27 articles (10/2019 - 06/2013)
6.	Symonds, William T: 27 articles (11/2015 - 01/2013)
7.	Hyland, Robert H: 22 articles (10/2020 - 01/2013)
8.	Subramanian, G Mani: 22 articles (03/2019 - 05/2013)
9.	Osinusi, Anu: 21 articles (10/2019 - 01/2014)
10.	Gane, Edward J: 20 articles (10/2020 - 01/2013)

Related Diseases

1.	Infections 01/01/2021 - "Real-world data show that sofosbuvir-based regimens are highly effective and safe for patients with HCV genotypes 3 and 6 infections." 01/01/2020 - "Sofosbuvir-based regimens in the treatment of patients with chronic HCV infection were highly efficacious with excellent safety and tolerability profiles in a real-world setting; however, further research is required to establish whether or not such a regimen is an adequate treatment for all genotype 6 patients." 01/01/2015 - "Sofosbuvir is the first available once-daily NS5B polymerase inhibitor which has been approved in combination with PEG-IFN/RBV for just 12 weeks with 89% SVR in treatment-naïve patients with genotype 1 infection and 83-100% in treatment-experienced patients with genotypes 2/3. The current review focuses on the recent rapid and continuous developments in the management of chronic HCV infection with DAAs in combination with PEG-IFN/RBV." 01/01/2017 - "In the real-life setting, Sofosbuvir based regimens for 24 weeks has established an efficacious and well tolerated treatment in naïve and experienced patients with chronic HCV genotype 4 infection; although shorter treatment durations may be possible. " 10/01/2015 - "Sofosbuvir was safe and effective in the treatment of hepatitis C virus genotype 1, 2, 3, or 4 infections. "
2.	Hepatitis C 10/13/2017 - "However, several small-sized studies have been published on the safety and efficacy of sofosbuvir-based regimens for patients with hepatitis C on maintenance dialysis; overall, the viral response was satisfactory (SVR12 rates ranging between 58% and 100%) with a few drug-related drop-outs. " 03/28/2017 - "Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States." 04/01/2015 - "Sofosbuvir is a cost-effective treatment option for patients with hepatitis C." 10/01/2014 - "This paper, developed parallel to the approval of sofosbuvir, is to serve as a guidance for the therapeutic management of chronic hepatitis C. " 05/01/2018 - "Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study."
3.	Fibrosis (Cirrhosis) 01/01/2017 - "Sofosbuvir-containing regimens are effective in Chinese HCV patients with decompensated cirrhosis, regardless of baseline characteristics, as demonstrated by a high rate of SVR 12, as well as improvement in liver function. " 11/01/2020 - "The universal, pangenotypic combo of coblopasvir plus sofosbuvir is an efficacious and safe treatment for Chinese patients monoinfected with HCV of genotype 1, 2, 3 and 6, including those with compensated cirrhosis. " 09/02/2022 - "Study to investigate the effectiveness and safety of sofosbuvir-containing regimens in a prospective cohort of patients with HCV decompensated cirrhosis. " 01/01/2017 - "Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study." 01/01/2017 - "Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials."
4.	Chronic Hepatitis C 01/01/2018 - "The combination of sofosbuvir (SOF) plus an NS5A inhibitor for 12 weeks is highly efficacious in patients with chronic hepatitis C. " 01/01/2021 - "Sofosbuvir based regimens were effective and safe in the treatment of cirrhotic patients with chronic hepatitis C genotype 4." 02/01/2023 - "The efficacy of sofosbuvir (SOF)-based regimens in the treatment of chronic hepatitis C (HCV) patients with and without human immunodeficiency virus (HIV) co-infected patients in real-world setting is limited. " 03/01/2017 - "Sofosbuvir-based regimens have improved treatment success in chronic hepatitis C. " 01/01/2022 - "We recruited sofosbuvir-treated patients with chronic hepatitis C from five Canadian treatment sites, and performed a case-control pharmacogenomics study assessing both previously published and novel genetic polymorphisms. "
5.	COVID-19 12/16/2020 - "Incorporation of sofosbuvir-TP is very low, suggesting that sofosbuvir may not be very effective in treating SARS-CoV-2 infection. " 03/01/2022 - "Effect of sofosbuvir-based treatment on clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials." 03/25/2021 - "The aim of this study was to assess if Sofosbuvir improves clinical outcomes in patients with moderate or severe COVID-19. " 01/01/2021 - "With ongoing trials on Sofosbuvir in covid 19 treatment, our finding, albeit coincidental, points to the possible role even in immune-compromised children." 01/01/2021 - "Out of many clinical trials registered, there are ongoing human studies highlighting Sofosbuvir's possible role in the treatment of Covid-19 (Coronavirus Disease 2019). "

Related Drugs and Biologics

1.	Ribavirin (Virazole)
2.	daclatasvir
3.	velpatasvir
4.	ledipasvir
5.	Simeprevir
6.	Antiviral Agents (Antivirals)
7.	Interferons
8.	sofosbuvir drug combination ledipasvir
9.	Nucleotides
10.	paritaprevir

Related Therapies and Procedures

1.	Therapeutics
2.	Liver Transplantation
3.	Renal Dialysis (Hemodialysis)
4.	Retreatment
5.	Transplantation